Tongling Jieya Biologic Technology Co., Ltd. (SHE:301108)
China
· Delayed Price · Currency is CNY 30.50
-0.45 (-1.45%)
At close: Mar 9, 2026
SHE:301108 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2019 - 2017 |
| Operating Revenue | 696.23 | 539.42 | 592.39 | 648.31 | 970.23 | 737.73 | Upgrade
|
| Other Revenue | 8.03 | 8.03 | 30.2 | 18.25 | 14.22 | 5.29 | Upgrade
|
| Revenue | 704.26 | 547.45 | 622.59 | 666.56 | 984.45 | 743.01 | Upgrade
|
| Revenue Growth (YoY) | 20.74% | -12.07% | -6.60% | -32.29% | 32.50% | 141.70% | Upgrade
|
| Cost of Revenue | 541.81 | 448.21 | 442.27 | 461.97 | 667.87 | 479.3 | Upgrade
|
| Gross Profit | 162.45 | 99.24 | 180.32 | 204.59 | 316.58 | 263.72 | Upgrade
|
| Selling, General & Admin | 58.85 | 51.46 | 55.68 | 38.91 | 29.1 | 19.42 | Upgrade
|
| Research & Development | 26.43 | 20.48 | 22.52 | 25.29 | 36.38 | 27.36 | Upgrade
|
| Other Operating Expenses | 4.89 | 0.56 | 0.72 | 4.86 | 7.13 | 3.4 | Upgrade
|
| Operating Expenses | 102.5 | 80.61 | 77.69 | 69.84 | 73.28 | 53.17 | Upgrade
|
| Operating Income | 59.95 | 18.63 | 102.63 | 134.75 | 243.31 | 210.55 | Upgrade
|
| Interest Expense | -1 | -0.77 | -1.01 | -1.86 | -1.62 | -0.61 | Upgrade
|
| Interest & Investment Income | 15.04 | 15.17 | 30.38 | 24.6 | 6.05 | 2.46 | Upgrade
|
| Currency Exchange Gain (Loss) | 2.51 | 2.51 | 1.22 | 6.2 | -6.89 | -13.47 | Upgrade
|
| Other Non Operating Income (Expenses) | -2.01 | 0.78 | -0.23 | -0.16 | -0.24 | -0.18 | Upgrade
|
| EBT Excluding Unusual Items | 74.49 | 36.32 | 133 | 163.52 | 240.61 | 198.74 | Upgrade
|
| Gain (Loss) on Sale of Investments | 1.96 | 5.5 | 9.06 | 1.01 | 1.2 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.17 | -0.03 | 0.32 | 1.15 | 0.29 | 0.57 | Upgrade
|
| Asset Writedown | -18.37 | -17.49 | -10.51 | -11.46 | -0.42 | -0.57 | Upgrade
|
| Other Unusual Items | 4.88 | 0.85 | 3.13 | 7.95 | 10.18 | 8.32 | Upgrade
|
| Pretax Income | 63.14 | 25.15 | 135.01 | 162.16 | 251.85 | 207.06 | Upgrade
|
| Income Tax Expense | 10.49 | 5.97 | 20.46 | 21.2 | 31.81 | 27.43 | Upgrade
|
| Earnings From Continuing Operations | 52.65 | 19.17 | 114.54 | 140.97 | 220.05 | 179.63 | Upgrade
|
| Minority Interest in Earnings | 0.04 | 0.29 | 0.66 | - | - | - | Upgrade
|
| Net Income | 52.68 | 19.46 | 115.2 | 140.97 | 220.05 | 179.63 | Upgrade
|
| Net Income to Common | 52.68 | 19.46 | 115.2 | 140.97 | 220.05 | 179.63 | Upgrade
|
| Net Income Growth | -6.43% | -83.10% | -18.28% | -35.94% | 22.50% | 163.69% | Upgrade
|
| Shares Outstanding (Basic) | 138 | 114 | 114 | 113 | 88 | 85 | Upgrade
|
| Shares Outstanding (Diluted) | 138 | 114 | 114 | 113 | 88 | 85 | Upgrade
|
| Shares Change (YoY) | 55.65% | -0.01% | 0.14% | 29.59% | 2.66% | 0.12% | Upgrade
|
| EPS (Basic) | 0.38 | 0.17 | 1.01 | 1.24 | 2.51 | 2.11 | Upgrade
|
| EPS (Diluted) | 0.38 | 0.17 | 1.01 | 1.24 | 2.51 | 2.11 | Upgrade
|
| EPS Growth | -39.88% | -83.10% | -18.39% | -50.57% | 19.32% | 163.39% | Upgrade
|
| Free Cash Flow | -233.27 | -21.11 | -1.54 | 269.1 | 127.59 | 84.36 | Upgrade
|
| Free Cash Flow Per Share | -1.69 | -0.19 | -0.01 | 2.37 | 1.46 | 0.99 | Upgrade
|
| Dividend Per Share | 0.171 | 0.071 | 0.257 | 0.357 | 0.536 | - | Upgrade
|
| Dividend Growth | -33.33% | -72.23% | -28.00% | -33.34% | - | - | Upgrade
|
| Gross Margin | 23.07% | 18.13% | 28.96% | 30.69% | 32.16% | 35.49% | Upgrade
|
| Operating Margin | 8.51% | 3.40% | 16.48% | 20.21% | 24.71% | 28.34% | Upgrade
|
| Profit Margin | 7.48% | 3.56% | 18.50% | 21.15% | 22.35% | 24.18% | Upgrade
|
| Free Cash Flow Margin | -33.12% | -3.86% | -0.25% | 40.37% | 12.96% | 11.35% | Upgrade
|
| EBITDA | 113.23 | 62.66 | 134.32 | 169.16 | 271.94 | 227.34 | Upgrade
|
| EBITDA Margin | 16.08% | 11.45% | 21.57% | 25.38% | 27.62% | 30.60% | Upgrade
|
| D&A For EBITDA | 53.28 | 44.03 | 31.69 | 34.41 | 28.63 | 16.79 | Upgrade
|
| EBIT | 59.95 | 18.63 | 102.63 | 134.75 | 243.31 | 210.55 | Upgrade
|
| EBIT Margin | 8.51% | 3.40% | 16.48% | 20.21% | 24.71% | 28.34% | Upgrade
|
| Effective Tax Rate | 16.62% | 23.75% | 15.16% | 13.07% | 12.63% | 13.25% | Upgrade
|
| Revenue as Reported | 704.26 | 547.45 | 622.59 | 666.56 | 984.45 | 743.01 | Upgrade
|
| Advertising Expenses | - | 0.06 | 0.4 | 0.18 | 0.05 | 0.11 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.